Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.

Gynecologic oncology - 1 Feb 2018

Bernards Sarah S, Pennington Kathryn P, Harrell Maria I, Agnew Kathy J, Garcia Rochelle L, Norquist Barbara M, Swisher Elizabeth M

Abstract excerpt

OBJECTIVE: In ovarian carcinoma, mutations in homologous recombination DNA repair (HRR) genes, including BRCA1 and RAD51C, are associated with increased survival and specific clinical features. Promoter hypermethylation is another mechanism of reducing gene expression. We assessed whether BRCA1 and RAD51C promoter hypermethylation is associated with similar survival and clinical characteristics. METHODS: Promoter...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to DNA Methylation

Share to Germ-Line Mutation

Share to Ovarian Neoplasms

Share to Platinum Compounds

Share to Promoter Regions, Genetic

Source

Identifiers

PMID: 29233532
DOI: 10.1016/j.ygyno.2017.12.004

Genes

BRCA1
HGS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.PMID 29233532Read ↗

Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status.Semantic proximity Read ↗

BRCA loss of function including BRCA1 DNA-methylation, but not BRCA-unrelated homologous recombination deficiency, is associated with platinum hypersensitivity in high-grade ovarian cancer.Semantic proximity Read ↗

Prognostic value of BRCA1 promoter methylation for patients with epithelial ovarian cancer.Semantic proximity Read ↗

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalitiesSemantic proximity Read ↗

Clinical characteristics and survival analysis of Chinese ovarian cancer patients with RAD51D germline mutationsSemantic proximity Read ↗

BRCA1 promoter methylation predicts adverse ovarian cancer prognosisSemantic proximity Read ↗

53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.Semantic proximity Read ↗

BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients – A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)Semantic proximity Read ↗

Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian CarcinomaSemantic proximity Read ↗

<i>BRCA1</i>epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancerSemantic proximity Read ↗

BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.Semantic proximity Read ↗

Clinical Relevance of BRCA1 Promoter Methylation Testing in Patients with Ovarian CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.